Navigation Links
Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
Date:12/21/2007

THE WOODLANDS, Texas, Dec. 21 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for LX1032, an oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. The initial Phase 1 clinical trial of LX1032 is planned as a double-blind, randomized, placebo-controlled, ascending single-dose study in healthy volunteers. This study is designed to evaluate the safety, tolerability, and pharmacokinetics of LX1032. Lexicon expects to initiate clinical trials with LX1032 following FDA review.

"We believe LX1032 has the potential to be an important new therapy in an area of high unmet medical need," said Philip M. Brown, M.D., J.D., vice president of clinical development at Lexicon. "LX1032 may offer important benefits to patients with carcinoid syndrome, who have very limited treatment options."

Carcinoid syndrome is the result of metastatic carcinoid tumors that usually originate from enterochromaffin cells in the lining of the gastrointestinal tract. These tumors secrete large amounts of serotonin, which causes a variety of symptoms that often includes severe diarrhea and abdominal discomfort. Carcinoid tumors are a type of neuroendocrine tumor and, according to the American Cancer Society, about 11,000 to 12,000 neuroendocrine tumors and neuroendocrine cancers are diagnosed each year in the United States. About 10% of people with carcinoid tumors will develop carcinoid syndrome.

The target for LX1032 was identified through the Genome5000(TM) project, Lexicon's program to identify the function of 5,000 druggable genes in the human genome. LX1032
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
2. Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Lexicon Appoints Judith Swain, M.D. to Board of Directors
4. Lexicon Pharmaceuticals to Present at ThinkEquity ThinkClinic
5. Lexicon Pharmaceuticals to Present at Bio InvestorForum
6. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
7. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
8. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
9. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Sales Horizons, a ... its online sales training course – Mastering the ... sales performance. , Drawn from proven sales training programs ... Mastering the Complex Sale online sales training course is ... who has face-to-face contact with customers, like technical support, ...
(Date:7/30/2014)... 30, 2014 W. R. Grace ... of the REVELERIS® Prep purification system , ... chromatographers, and other researchers to perform both flash ... unit. , With the REVELERIS® Prep purification system, ... chromatography modes with a simple touch of the ...
(Date:7/30/2014)... , July 30, 2014  The Chicago Bears ... American Academy of Dermatology (Academy) in an effort to ... Chicago Bears will host free SPOT me™ skin cancer ... 2 at Soldier Field. SPOT me™ is an ... about the dangers and risks of skin cancer, and ...
(Date:7/30/2014)... Selexis SA , a serial innovation company ... cell line development, announced today new data from the ... at the 10th Annual Cell Line Development and ... 2014 at the Double Tree by Hilton Berkeley Marina ... be presented during an oral presentation: , Title: Genome ...
Breaking Biology Technology:Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Grace Launches New REVELERIS® Prep Purification System 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3
... Diseases and,Disorders, OLDSMAR, Fla., Jan. 29 ... ("Cryo-Cell" or the "Company"), one of the,largest ... today announced that,it has formalized a research ... ("Saneron") that represents an important milestone in,efforts ...
... RESEARCH TRIANGLE PARK, N.C., Jan. 29 ,Merial Limited and ... under which Merial will screen a Chimerix chemical library ... agreement, Merial has an,option to negotiate a license with ... "This collaboration with Chimerix provides us with an opportunity ...
... year end; no equity financings expected in 2008, ... continue in,2008; latest data for all programs to be ... Expansion of research and development investment in pharmacological, ... 2008, CRANBURY, N.J., Jan. 29 Amicus Therapeutics,(Nasdaq: ...
Cached Biology Technology:Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc. 2Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc. 3Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc. 4Merial to Screen Chimerix' Chemical Library for Animal Health Drug Leads 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 3Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 4Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 5Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 6Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 7Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 8Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 9Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 10Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 11Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 12Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 13Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 14
(Date:7/30/2014)... simple as inserting a medicated, disappearing fabric minutes before ... discovered a potentially faster way to deliver a topical ... spins the drug into silk-like fibers that quickly dissolve ... the drug than possible with other topical materials such ... a potentially more effective, discreet way to protect themselves ...
(Date:7/30/2014)... NexID Biometrics , a leading ... for the biometric authentication industry, has recently joined ... authentication with standards for strong authentication. According to ... to join FIDO Alliance stems from NexID,s mission ... We believe the FIDO Alliance is a key ...
(Date:7/30/2014)... Press Limited today announced an across-the-board increase in ... The 2013 InCites Journal Citation Reports (Thomson Reuters, ... Biochemical Journal , Essays in Biochemistry , ... Reports all received increases in their Impact ... Society and published by Portland Press Limited. , ...
Breaking Biology News(10 mins):Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3NexID Biometrics Joins the FIDO Alliance 2Across-the-board Impact Factor increases for Portland Press Limited 2
... enhance threat and radiation detection, improve life sciences ... received recognition for their innovation today. R&D Magazine ... Department of Energy,s Pacific Northwest National Laboratory with ... selects the 100 most innovative scientific and technological ...
... KINGSTON, R.I. July 8, 2010 A new ... been developed by a team of University of Rhode ... that can be triggered by non-invasive electromagnetic fields. ... Bose and graduate student Yanjing Chen was published in ...
... (July 8, 2010) By solving the three-dimensional structure ... group of McMaster University researchers have revealed new avenues ... living with hereditary colorectal cancers. The finding, published ... important step forward in the field of molecular and ...
Cached Biology News:PNNL scientists win 4 R&D 100 awards for environment, biology, security technologies 2PNNL scientists win 4 R&D 100 awards for environment, biology, security technologies 3PNNL scientists win 4 R&D 100 awards for environment, biology, security technologies 4PNNL scientists win 4 R&D 100 awards for environment, biology, security technologies 5Researchers develop drug delivery system using nanoparticles triggered by electromagnetic field 2DNA discovery opens new door to develop tools, therapies for hereditary cancers 2